Karyopharm Therapeutics
KPTI
157 hedge funds and large institutions have $949M invested in Karyopharm Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 55 increasing their positions, 53 reducing their positions, and 27 closing their positions.
61% more call options, than puts
Call options by funds: $7.81M | Put options by funds: $4.85M
1% more funds holding
Funds holding: 155 → 157 (+2)
7% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 27
4% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 53
0.45% less ownership
Funds ownership: 6.36% → 5.91% (-0.45%)
28% less capital invested
Capital invested by funds: $1.32B → $949M (-$372M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$17.2M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$14.9M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$14.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$12.9M |
| 5 |
BlackRock
New York
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$123M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$25.3M |
| 3 |
Goldman Sachs
New York
|
-$18.5M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$16.3M |
| 5 |
D.E. Shaw & Co
New York
|
-$9.58M |
KPTI Hedge Fund Activity: Q3 2020 in Review
157 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2020, worth a combined $949M — down 28% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KPTI positions and 27 closed out — a net gain of 2 holders — while 55 added to existing stakes and 53 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $17.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $123M sold.
- 157 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2020, up from 155 in Q2 2020.
- Funds reported $949M of Karyopharm Therapeutics stock for Q3 2020, down 28% quarter-over-quarter.
- 29 funds opened new Karyopharm Therapeutics positions in Q3 2020 and 27 closed out, a net change of +2 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2020 was Two Sigma Investments, an estimated $17.2M added.
- The largest Karyopharm Therapeutics seller in Q3 2020 was Consonance Capital Management, an estimated $123M sold.
Based on aggregated 13F filings for Q3 2020.